Ann Arbor, MI – Esperion Therapeutics has announced the acquisition of Corstasis Therapeutics (https://corstasis.com/). According to the company announcement, Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease. With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases.

To learn more about Esperion Therapeutics, visit https://www.esperion.com/
Company LinkedIn Page: https://www.linkedin.com/company/esperion-therapeutics/

Company Contact:

Esperion Therapeutics
3891 Ranchero Dr Suite 150
Ann Arbor, MI 48108
734-887-3903

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.